Share Price and Basic Stock Data
Last Updated: January 23, 2026, 9:29 pm
| PEG Ratio | 0.74 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Syncom Formulations (India) Ltd operates in the pharmaceuticals sector and reported a market capitalization of ₹1,103 Cr. The company’s revenue from operations has shown a positive trajectory, with sales rising from ₹222 Cr in FY 2023 to ₹257 Cr in FY 2024, and projected to reach ₹461 Cr in FY 2025. Quarterly sales figures indicate consistent growth, with ₹62 Cr recorded in September 2023, increasing to ₹63 Cr in December 2023. By March 2025, sales are expected to reach ₹148 Cr, reflecting a robust growth strategy. The company’s operating profit margin (OPM) stood at 12% for FY 2024, indicating an ability to maintain profitability amid rising operational costs. The trend of increasing sales is supported by a strong demand for pharmaceutical products, which positions Syncom favorably in a competitive market.
Profitability and Efficiency Metrics
Syncom Formulations reported a net profit of ₹20 Cr for FY 2023, which rose to ₹24 Cr in FY 2024, and is projected to reach ₹49 Cr in FY 2025. The net profit margin improved to 10.63% in FY 2025, showcasing enhanced profitability relative to sales. The company’s return on equity (ROE) stood at 15.5%, while the return on capital employed (ROCE) was reported at 18.6%, both indicating effective management of shareholder funds and capital. Furthermore, the interest coverage ratio (ICR) was exceptionally high at 82.74x, reflecting minimal debt obligations and a strong capacity to meet interest expenses. However, the cash conversion cycle (CCC) of 83 days suggests potential inefficiencies in managing working capital, as it is higher than the typical sector range, which could indicate room for improvement in operational efficiency.
Balance Sheet Strength and Financial Ratios
The balance sheet of Syncom Formulations demonstrates significant strength, with total borrowings reported at ₹0 Cr, indicating a lack of leverage and financial risk. The company’s reserves increased from ₹162 Cr in FY 2023 to ₹246 Cr in FY 2025, providing a solid buffer for future investments and operational needs. The price-to-book value (P/BV) ratio stood at 4.52x, which is on the higher side compared to typical sector norms, suggesting that the stock may be overvalued or that investors are pricing in future growth expectations. The current ratio of 4.55x indicates strong liquidity, significantly above the typical threshold of 1.5x for healthy businesses, which enhances the company’s ability to cover short-term liabilities. However, the reported inventory turnover ratio of 14.90x suggests effective inventory management, which is crucial for maintaining operational efficiency in the competitive pharmaceutical landscape.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Syncom Formulations indicates a stable control by promoters, who hold 50.57% of the total shares. This level of promoter holding typically instills confidence among investors regarding the management’s commitment to the company. Institutional investor participation remains low, with foreign institutional investors (FIIs) holding just 0.10% as of December 2024, which may reflect a cautious approach to the stock among larger investors. The total number of shareholders stood at 4,57,364, demonstrating a growing interest from the public. The absence of dividends in recent years may raise concerns among income-focused investors, but it also suggests that the company is reinvesting profits for growth. The slight decline in public shareholding from 49.44% in June 2023 to 49.33% in September 2025 indicates a marginal shift in investor sentiment, potentially reflecting broader market trends.
Outlook, Risks, and Final Insight
Looking ahead, Syncom Formulations is positioned for continued growth, particularly with increasing sales and profitability metrics. However, the company faces risks related to operational inefficiencies, as indicated by its cash conversion cycle, which may hinder liquidity in times of increased demand. Additionally, low institutional investor participation could impact stock performance, particularly during market volatility. The lack of dividend payouts may also deter certain investor segments. Nevertheless, the absence of debt and strong liquidity ratios provide a solid foundation for navigating potential challenges. In scenarios where operational efficiencies are improved, Syncom could enhance profitability further, while maintaining its growth trajectory. Conversely, persistent inefficiencies or adverse market conditions could challenge the company’s performance and investor confidence.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 99.9 | 198/84.3 | 27.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,451 Cr. | 318 | 479/192 | 71.5 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.6 Cr. | 43.9 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 61.0 Cr. | 41.7 | 43.4/17.0 | 145 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,523.94 Cr | 1,087.19 | 47.42 | 202.32 | 0.38% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 54 | 57 | 61 | 59 | 62 | 63 | 73 | 87 | 101 | 127 | 148 | 117 | 121 |
| Expenses | 50 | 51 | 55 | 53 | 56 | 57 | 64 | 76 | 90 | 112 | 131 | 101 | 103 |
| Operating Profit | 4 | 6 | 6 | 6 | 6 | 7 | 9 | 10 | 12 | 15 | 17 | 16 | 19 |
| OPM % | 8% | 10% | 10% | 10% | 10% | 11% | 12% | 12% | 12% | 11% | 12% | 14% | 15% |
| Other Income | 3 | 2 | 7 | 2 | 4 | 4 | 3 | 1 | 4 | 4 | 7 | 6 | 5 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 5 | 6 | 10 | 6 | 8 | 9 | 9 | 10 | 15 | 17 | 23 | 20 | 22 |
| Tax % | 33% | 30% | 18% | 27% | 24% | 25% | 27% | 24% | 25% | 24% | 24% | 22% | 25% |
| Net Profit | 4 | 4 | 8 | 4 | 6 | 6 | 7 | 8 | 11 | 13 | 18 | 16 | 17 |
| EPS in Rs | 0.04 | 0.04 | 0.09 | 0.05 | 0.07 | 0.07 | 0.07 | 0.08 | 0.12 | 0.14 | 0.19 | 0.17 | 0.18 |
Last Updated: January 10, 2026, 10:33 am
Below is a detailed analysis of the quarterly data for Syncom Formulations (India) Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 121.00 Cr.. The value appears strong and on an upward trend. It has increased from 117.00 Cr. (Jun 2025) to 121.00 Cr., marking an increase of 4.00 Cr..
- For Expenses, as of Sep 2025, the value is 103.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 101.00 Cr. (Jun 2025) to 103.00 Cr., marking an increase of 2.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 19.00 Cr.. The value appears strong and on an upward trend. It has increased from 16.00 Cr. (Jun 2025) to 19.00 Cr., marking an increase of 3.00 Cr..
- For OPM %, as of Sep 2025, the value is 15.00%. The value appears strong and on an upward trend. It has increased from 14.00% (Jun 2025) to 15.00%, marking an increase of 1.00%.
- For Other Income, as of Sep 2025, the value is 5.00 Cr.. The value appears to be declining and may need further review. It has decreased from 6.00 Cr. (Jun 2025) to 5.00 Cr., marking a decrease of 1.00 Cr..
- For Interest, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Depreciation, as of Sep 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 1.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 22.00 Cr.. The value appears strong and on an upward trend. It has increased from 20.00 Cr. (Jun 2025) to 22.00 Cr., marking an increase of 2.00 Cr..
- For Tax %, as of Sep 2025, the value is 25.00%. The value appears to be increasing, which may not be favorable. It has increased from 22.00% (Jun 2025) to 25.00%, marking an increase of 3.00%.
- For Net Profit, as of Sep 2025, the value is 17.00 Cr.. The value appears strong and on an upward trend. It has increased from 16.00 Cr. (Jun 2025) to 17.00 Cr., marking an increase of 1.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.18. The value appears strong and on an upward trend. It has increased from 0.17 (Jun 2025) to 0.18, marking an increase of 0.01.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:33 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 151 | 173 | 184 | 185 | 159 | 187 | 206 | 245 | 216 | 222 | 257 | 461 | 513 |
| Expenses | 135 | 155 | 167 | 168 | 147 | 175 | 189 | 207 | 196 | 202 | 229 | 407 | 447 |
| Operating Profit | 16 | 18 | 17 | 16 | 12 | 12 | 17 | 38 | 20 | 20 | 28 | 54 | 67 |
| OPM % | 11% | 11% | 9% | 9% | 7% | 6% | 8% | 16% | 9% | 9% | 11% | 12% | 13% |
| Other Income | 1 | 1 | 3 | 3 | 4 | 5 | 5 | 7 | 12 | 15 | 13 | 17 | 22 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 3 | 5 | 1 | 1 |
| Depreciation | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 |
| Profit before tax | 14 | 16 | 16 | 16 | 12 | 13 | 17 | 41 | 26 | 27 | 32 | 65 | 83 |
| Tax % | 33% | 38% | 36% | 33% | 28% | 12% | 18% | 28% | 24% | 24% | 26% | 24% | |
| Net Profit | 9 | 10 | 10 | 11 | 9 | 11 | 14 | 29 | 20 | 20 | 24 | 49 | 63 |
| EPS in Rs | 0.12 | 0.13 | 0.13 | 0.14 | 0.11 | 0.14 | 0.18 | 0.37 | 0.23 | 0.21 | 0.25 | 0.52 | 0.68 |
| Dividend Payout % | 17% | 16% | 15% | 15% | 0% | 0% | 0% | 0% | 13% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 11.11% | 0.00% | 10.00% | -18.18% | 22.22% | 27.27% | 107.14% | -31.03% | 0.00% | 20.00% | 104.17% |
| Change in YoY Net Profit Growth (%) | 0.00% | -11.11% | 10.00% | -28.18% | 40.40% | 5.05% | 79.87% | -138.18% | 31.03% | 20.00% | 84.17% |
Syncom Formulations (India) Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 18% |
| 3 Years: | 29% |
| TTM: | 73% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 28% |
| 3 Years: | 35% |
| TTM: | 111% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 59% |
| 3 Years: | 26% |
| 1 Year: | -23% |
| Return on Equity | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 12% |
| 3 Years: | 11% |
| Last Year: | 16% |
Last Updated: September 5, 2025, 1:41 pm
Balance Sheet
Last Updated: December 4, 2025, 2:04 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 78 | 78 | 78 | 78 | 78 | 78 | 78 | 79 | 86 | 94 | 94 | 94 | 94 |
| Reserves | 17 | 22 | 31 | 36 | 44 | 55 | 68 | 109 | 136 | 162 | 192 | 246 | 282 |
| Borrowings | 3 | 6 | 6 | 12 | 12 | 9 | 2 | 62 | 58 | 83 | 72 | 4 | 0 |
| Other Liabilities | 42 | 31 | 61 | 48 | 37 | 32 | 33 | 42 | 28 | 38 | 33 | 66 | 74 |
| Total Liabilities | 140 | 138 | 175 | 175 | 171 | 173 | 181 | 292 | 308 | 377 | 392 | 410 | 451 |
| Fixed Assets | 50 | 46 | 46 | 85 | 89 | 89 | 93 | 91 | 94 | 91 | 120 | 125 | 124 |
| CWIP | 0 | 0 | 5 | 0 | 1 | 0 | 0 | 0 | 6 | 26 | 0 | 0 | 8 |
| Investments | 9 | 6 | 23 | 1 | 2 | 2 | 1 | 11 | 43 | 64 | 66 | 93 | 148 |
| Other Assets | 80 | 85 | 101 | 89 | 79 | 83 | 87 | 189 | 165 | 196 | 206 | 192 | 171 |
| Total Assets | 140 | 138 | 175 | 175 | 171 | 173 | 181 | 292 | 308 | 377 | 392 | 410 | 451 |
Below is a detailed analysis of the balance sheet data for Syncom Formulations (India) Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 94.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 94.00 Cr..
- For Reserves, as of Sep 2025, the value is 282.00 Cr.. The value appears strong and on an upward trend. It has increased from 246.00 Cr. (Mar 2025) to 282.00 Cr., marking an increase of 36.00 Cr..
- For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 4.00 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 4.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 74.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 66.00 Cr. (Mar 2025) to 74.00 Cr., marking an increase of 8.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 451.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 410.00 Cr. (Mar 2025) to 451.00 Cr., marking an increase of 41.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 124.00 Cr.. The value appears to be declining and may need further review. It has decreased from 125.00 Cr. (Mar 2025) to 124.00 Cr., marking a decrease of 1.00 Cr..
- For CWIP, as of Sep 2025, the value is 8.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 8.00 Cr., marking an increase of 8.00 Cr..
- For Investments, as of Sep 2025, the value is 148.00 Cr.. The value appears strong and on an upward trend. It has increased from 93.00 Cr. (Mar 2025) to 148.00 Cr., marking an increase of 55.00 Cr..
- For Other Assets, as of Sep 2025, the value is 171.00 Cr.. The value appears to be declining and may need further review. It has decreased from 192.00 Cr. (Mar 2025) to 171.00 Cr., marking a decrease of 21.00 Cr..
- For Total Assets, as of Sep 2025, the value is 451.00 Cr.. The value appears strong and on an upward trend. It has increased from 410.00 Cr. (Mar 2025) to 451.00 Cr., marking an increase of 41.00 Cr..
Notably, the Reserves (282.00 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 13.00 | 12.00 | 11.00 | 4.00 | 0.00 | 3.00 | 15.00 | -24.00 | -38.00 | -63.00 | -44.00 | 50.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 71 | 66 | 91 | 91 | 87 | 81 | 77 | 112 | 114 | 124 | 132 | 85 |
| Inventory Days | 36 | 34 | 43 | 29 | 37 | 37 | 39 | 51 | 51 | 53 | 49 | 49 |
| Days Payable | 105 | 63 | 130 | 92 | 75 | 57 | 49 | 66 | 36 | 52 | 33 | 51 |
| Cash Conversion Cycle | 1 | 37 | 4 | 27 | 49 | 61 | 67 | 96 | 129 | 124 | 148 | 83 |
| Working Capital Days | 75 | 84 | 40 | 45 | 75 | 74 | 88 | 28 | 33 | -4 | 51 | 95 |
| ROCE % | 15% | 16% | 15% | 14% | 9% | 9% | 12% | 21% | 11% | 10% | 10% | 19% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF | 5,387 | 0.09 | 0.01 | 5,387 | 2025-04-22 16:59:38 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 17 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 0.57 | 0.34 | 0.24 | 0.26 | 0.13 |
| Diluted EPS (Rs.) | 0.57 | 0.34 | 0.24 | 0.24 | 0.13 |
| Cash EPS (Rs.) | 0.58 | 0.31 | 0.26 | 0.27 | 0.17 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 3.64 | 3.07 | 2.72 | 2.58 | 1.50 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 3.64 | 3.07 | 2.72 | 2.58 | 1.50 |
| Revenue From Operations / Share (Rs.) | 4.95 | 2.80 | 2.39 | 2.55 | 2.37 |
| PBDIT / Share (Rs.) | 0.76 | 0.45 | 0.36 | 0.37 | 0.24 |
| PBIT / Share (Rs.) | 0.70 | 0.40 | 0.31 | 0.32 | 0.20 |
| PBT / Share (Rs.) | 0.69 | 0.36 | 0.28 | 0.30 | 0.20 |
| Net Profit / Share (Rs.) | 0.52 | 0.26 | 0.21 | 0.22 | 0.13 |
| NP After MI And SOA / Share (Rs.) | 0.52 | 0.26 | 0.21 | 0.22 | 0.13 |
| PBDIT Margin (%) | 15.39 | 16.39 | 15.26 | 14.58 | 10.43 |
| PBIT Margin (%) | 14.27 | 14.59 | 13.23 | 12.78 | 8.74 |
| PBT Margin (%) | 14.08 | 12.89 | 11.84 | 11.91 | 8.59 |
| Net Profit Margin (%) | 10.63 | 9.61 | 8.94 | 9.00 | 5.69 |
| NP After MI And SOA Margin (%) | 10.63 | 9.61 | 8.94 | 9.00 | 5.69 |
| Return on Networth / Equity (%) | 14.44 | 8.78 | 7.83 | 8.90 | 8.97 |
| Return on Capital Employeed (%) | 18.75 | 12.89 | 11.21 | 12.20 | 12.92 |
| Return On Assets (%) | 11.96 | 6.25 | 5.31 | 6.42 | 5.84 |
| Total Debt / Equity (X) | 0.01 | 0.25 | 0.32 | 0.26 | 0.10 |
| Asset Turnover Ratio (%) | 1.14 | 0.67 | 0.65 | 0.00 | 1.05 |
| Current Ratio (X) | 4.55 | 2.58 | 1.61 | 1.79 | 1.50 |
| Quick Ratio (X) | 3.85 | 2.38 | 1.42 | 1.54 | 1.32 |
| Inventory Turnover Ratio (X) | 14.90 | 6.22 | 4.89 | 0.00 | 5.42 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 14.82 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 11.43 |
| Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 85.18 |
| Cash Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 88.57 |
| Interest Coverage Ratio (X) | 82.74 | 9.65 | 10.93 | 16.62 | 68.46 |
| Interest Coverage Ratio (Post Tax) (X) | 58.15 | 6.66 | 7.41 | 11.25 | 38.42 |
| Enterprise Value (Cr.) | 1550.17 | 1055.54 | 629.15 | 974.19 | 159.72 |
| EV / Net Operating Revenue (X) | 3.33 | 4.01 | 2.81 | 4.43 | 0.86 |
| EV / EBITDA (X) | 21.66 | 24.45 | 18.38 | 30.42 | 8.28 |
| MarketCap / Net Operating Revenue (X) | 3.33 | 3.99 | 2.47 | 4.17 | 0.83 |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 0.00 | 85.17 |
| Price / BV (X) | 4.52 | 3.65 | 2.17 | 4.13 | 1.31 |
| Price / Net Operating Revenue (X) | 3.33 | 3.99 | 2.47 | 4.17 | 0.83 |
| EarningsYield | 0.03 | 0.02 | 0.03 | 0.02 | 0.06 |
After reviewing the key financial ratios for Syncom Formulations (India) Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.57. This value is below the healthy minimum of 5. It has increased from 0.34 (Mar 24) to 0.57, marking an increase of 0.23.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.57. This value is below the healthy minimum of 5. It has increased from 0.34 (Mar 24) to 0.57, marking an increase of 0.23.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.58. This value is below the healthy minimum of 3. It has increased from 0.31 (Mar 24) to 0.58, marking an increase of 0.27.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 3.64. It has increased from 3.07 (Mar 24) to 3.64, marking an increase of 0.57.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 3.64. It has increased from 3.07 (Mar 24) to 3.64, marking an increase of 0.57.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 4.95. It has increased from 2.80 (Mar 24) to 4.95, marking an increase of 2.15.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.76. This value is below the healthy minimum of 2. It has increased from 0.45 (Mar 24) to 0.76, marking an increase of 0.31.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.70. This value is within the healthy range. It has increased from 0.40 (Mar 24) to 0.70, marking an increase of 0.30.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.69. This value is within the healthy range. It has increased from 0.36 (Mar 24) to 0.69, marking an increase of 0.33.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.52. This value is below the healthy minimum of 2. It has increased from 0.26 (Mar 24) to 0.52, marking an increase of 0.26.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.52. This value is below the healthy minimum of 2. It has increased from 0.26 (Mar 24) to 0.52, marking an increase of 0.26.
- For PBDIT Margin (%), as of Mar 25, the value is 15.39. This value is within the healthy range. It has decreased from 16.39 (Mar 24) to 15.39, marking a decrease of 1.00.
- For PBIT Margin (%), as of Mar 25, the value is 14.27. This value is within the healthy range. It has decreased from 14.59 (Mar 24) to 14.27, marking a decrease of 0.32.
- For PBT Margin (%), as of Mar 25, the value is 14.08. This value is within the healthy range. It has increased from 12.89 (Mar 24) to 14.08, marking an increase of 1.19.
- For Net Profit Margin (%), as of Mar 25, the value is 10.63. This value exceeds the healthy maximum of 10. It has increased from 9.61 (Mar 24) to 10.63, marking an increase of 1.02.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 10.63. This value is within the healthy range. It has increased from 9.61 (Mar 24) to 10.63, marking an increase of 1.02.
- For Return on Networth / Equity (%), as of Mar 25, the value is 14.44. This value is below the healthy minimum of 15. It has increased from 8.78 (Mar 24) to 14.44, marking an increase of 5.66.
- For Return on Capital Employeed (%), as of Mar 25, the value is 18.75. This value is within the healthy range. It has increased from 12.89 (Mar 24) to 18.75, marking an increase of 5.86.
- For Return On Assets (%), as of Mar 25, the value is 11.96. This value is within the healthy range. It has increased from 6.25 (Mar 24) to 11.96, marking an increase of 5.71.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.01. This value is within the healthy range. It has decreased from 0.25 (Mar 24) to 0.01, marking a decrease of 0.24.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.14. It has increased from 0.67 (Mar 24) to 1.14, marking an increase of 0.47.
- For Current Ratio (X), as of Mar 25, the value is 4.55. This value exceeds the healthy maximum of 3. It has increased from 2.58 (Mar 24) to 4.55, marking an increase of 1.97.
- For Quick Ratio (X), as of Mar 25, the value is 3.85. This value exceeds the healthy maximum of 2. It has increased from 2.38 (Mar 24) to 3.85, marking an increase of 1.47.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 14.90. This value exceeds the healthy maximum of 8. It has increased from 6.22 (Mar 24) to 14.90, marking an increase of 8.68.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 82.74. This value is within the healthy range. It has increased from 9.65 (Mar 24) to 82.74, marking an increase of 73.09.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 58.15. This value is within the healthy range. It has increased from 6.66 (Mar 24) to 58.15, marking an increase of 51.49.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,550.17. It has increased from 1,055.54 (Mar 24) to 1,550.17, marking an increase of 494.63.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.33. This value exceeds the healthy maximum of 3. It has decreased from 4.01 (Mar 24) to 3.33, marking a decrease of 0.68.
- For EV / EBITDA (X), as of Mar 25, the value is 21.66. This value exceeds the healthy maximum of 15. It has decreased from 24.45 (Mar 24) to 21.66, marking a decrease of 2.79.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.33. This value exceeds the healthy maximum of 3. It has decreased from 3.99 (Mar 24) to 3.33, marking a decrease of 0.66.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is 4.52. This value exceeds the healthy maximum of 3. It has increased from 3.65 (Mar 24) to 4.52, marking an increase of 0.87.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.33. This value exceeds the healthy maximum of 3. It has decreased from 3.99 (Mar 24) to 3.33, marking a decrease of 0.66.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has increased from 0.02 (Mar 24) to 0.03, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Syncom Formulations (India) Ltd:
- Net Profit Margin: 10.63%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 18.75% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 14.44% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 58.15
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.85
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 17.9 (Industry average Stock P/E: 47.42)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.01
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 10.63%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 7, Niraj Industrial Estate, Off Mahakali Caves Road, Mumbai Maharashtra 400093 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Ankit Kedarmal Bankda | Executive Chairman & Whole-time Director |
| Mr. Vijay Shankarlal Bankda | Managing Director |
| Mr. Kedarmal Shankarlal Bankda | Whole Time Director |
| Mrs. Ruchi Jindal | Independent Woman Director |
| Mr. Ritesh Kumar Lunkad | Independent Director |
| Mr. Ankit Jain | Independent Director |
FAQ
What is the intrinsic value of Syncom Formulations (India) Ltd?
Syncom Formulations (India) Ltd's intrinsic value (as of 23 January 2026) is ₹11.25 which is 5.46% lower the current market price of ₹11.90, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹1,125 Cr. market cap, FY2025-2026 high/low of ₹23.5/11.5, reserves of ₹282 Cr, and liabilities of ₹451 Cr.
What is the Market Cap of Syncom Formulations (India) Ltd?
The Market Cap of Syncom Formulations (India) Ltd is 1,125 Cr..
What is the current Stock Price of Syncom Formulations (India) Ltd as on 23 January 2026?
The current stock price of Syncom Formulations (India) Ltd as on 23 January 2026 is ₹11.9.
What is the High / Low of Syncom Formulations (India) Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Syncom Formulations (India) Ltd stocks is ₹23.5/11.5.
What is the Stock P/E of Syncom Formulations (India) Ltd?
The Stock P/E of Syncom Formulations (India) Ltd is 17.9.
What is the Book Value of Syncom Formulations (India) Ltd?
The Book Value of Syncom Formulations (India) Ltd is 4.00.
What is the Dividend Yield of Syncom Formulations (India) Ltd?
The Dividend Yield of Syncom Formulations (India) Ltd is 0.00 %.
What is the ROCE of Syncom Formulations (India) Ltd?
The ROCE of Syncom Formulations (India) Ltd is 18.6 %.
What is the ROE of Syncom Formulations (India) Ltd?
The ROE of Syncom Formulations (India) Ltd is 15.5 %.
What is the Face Value of Syncom Formulations (India) Ltd?
The Face Value of Syncom Formulations (India) Ltd is 1.00.